Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia
Eiger BioPharmaceuticals, Inc. (EIGR)
Last eiger biopharmaceuticals, inc. earnings: 3/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.eigerbio.com
Company Research
Source: PR Newswire
PALO ALTO, Calif., Aug. 13, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 PREVENT study. PREVENT is a multi-center, placebo-controlled study investigating the safety and durability of effect of subcutaneous (SC) avexitide (formerly exendin 9-39) in post-bariatric surgical patients who experience dangerously low, postprandial blood glucose levels (hypoglycemia) known as post-bariatric hypoglycemia (PBH). A total of 18 patients were enrolled across five study sites in the United States. There is currently no FDA approved pharmacologic therapy for PBH. At Eiger's request, avexitide has recently been adopted by the United States Adopted Name (USAN) Council and will be the International Nonproprietary Name (INN), which is used to identify pharmaceutical substances or active pharmaceutical ingredients. Ea
Show less
Read more
Impact Snapshot
Event Time:
EIGR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EIGR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EIGR alerts
High impacting Eiger BioPharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EIGR
News
- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- BRNS, UPC and KWE among mid-day movers [Seeking Alpha]Seeking Alpha
- Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection [Yahoo! Finance]Yahoo! Finance
- Eiger BioPharmaceuticals Files for Voluntary Chapter 11 ProtectionGlobeNewswire
- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
EIGR
Sec Filings
- 4/8/24 - Form 10-K
- 4/3/24 - Form 8-K
- 4/1/24 - Form NT
- EIGR's page on the SEC website